Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome for Older Patients with Less Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple Myeloma

Blood (2016) 128 (22): 516.

https://doi.org/10.1182/blood.V128.22.516.516

Published: 2016

Journal Articles

Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study

Martin Kropff, MD, Martin Vogel, MD PhD, Andrea Kreter, Dipl. Stat., Rudolf Schlag, Lothar Müller, MD, Rudolf Weide, MD, Wolfgang Knauf, MD PhD, Thomas Decker, MD, Heinrich Fiechtner, PhD, Georgi Kojouharoff, MD, Stephan Kremers, MD, Wolfgang E Berdel, MD

Blood (2014) 124 (21): 3470.

https://doi.org/10.1182/blood.V124.21.3470.3470

Published: 2014

Journal Articles

Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Multiple Myeloma

Blood (2014) 124 (21): 3969.

https://doi.org/10.1182/blood.V124.21.3969.3969

Published: 2014

Journal Articles

PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study

Meletios A. Dimopoulos, MD, Maria Teresa Petrucci, MD, Robin Foà, MD, John V. Catalano, MD, Martin Kropff, MD, Zhinuan Yu, PhD, Lara Grote, Christian J. Jacques, MD, Antonio Palumbo, MD

Blood (2013) 122 (21): 405.

https://doi.org/10.1182/blood.V122.21.405.405

Published: 2013

Journal Articles

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

Blood (2012) 120 (21): 2012.

https://doi.org/10.1182/blood.V120.21.2012.2012

Published: 2012

Journal Articles

Analysis of Second-Line Lenalidomide Following Initial Relapse in the MM-015 Trial

Meletios A Dimopoulos, MD, Maria Teresa Petrucci, MD, Robin Foa, MD, John V. Catalano, MD, Martin Kropff, MD, Zhinuan Yu, PhD, Lindsay Herbein, BS, Christian J. Jacques, MD, Antonio Palumbo, MD

Blood (2012) 120 (21): 944.

https://doi.org/10.1182/blood.V120.21.944.944

Published: 2012

Journal Articles

Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years,

Meletios Athanasios Dimopoulos, MD, Antonio Palumbo, MD, Roman Hajek, MD, PhD, Martin Kropff, MD, Maria Teresa Petrucci, MD, Philip Lewis, PhD, Stefanie Millar, Jingshan Zhang, PhD, Jay Mei, MD, PhD, Michel Delforge, MD, PhD

Blood (2011) 118 (21): 3988.

https://doi.org/10.1182/blood.V118.21.3988.3988

Published: 2011

Journal Articles

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65–75 Yrs Enrolled in MM-015

Blood (2011) 118 (21): 475.

https://doi.org/10.1182/blood.V118.21.475.475

Published: 2011

Journal Articles

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Blood (2011) 118 (21): 476.

https://doi.org/10.1182/blood.V118.21.476.476

Published: 2011

Journal Articles

Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression

Meletios Athanasios Dimopoulos, MD, Michel Delforge, MD, PhD, Roman Hajek, MD, PhD, Martin Kropff, MD, Maria Teresa Petrucci, MD, Philip Lewis, PhD, Stefanie Millar, Jingshan Zhang, PhD, Jay Mei, MD, PhD, Antonio Palumbo, MD

Blood (2011) 118 (21): 3157.

https://doi.org/10.1182/blood.V118.21.3157.3157

Published: 2011

Journal Articles

Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients

Nicolaus Kröger, Evgeny Klyuchnikov, MD, Thomas Stübig, MD, Christine Wolschke, MD, Francis Ayuk, MD, Tatjana Zabelina, MD, York Hildebrandt, Ulrike Bacher, MD, Anita Badbaran, Georgia Schilling, MD, Orhan Sezer, MD, PhD, Djordje Atanackovic, M.D., Martin Kropff, MD, Axel R. Zander, MD

Blood (2011) 118 (21): 3024.

https://doi.org/10.1182/blood.V118.21.3024.3024

Published: 2011

Journal Articles

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens

Antonio Palumbo, MD, Michel Delforge, MD, PhD, John Catalano, MBBS, FRACP, FRCPA, Roman Hajek, MD, PhD, Martin Kropff, MD, Maria Teresa Petrucci, Zhinuan Yu, Lindsey Herbein, Jay M. Mei, MD, PhD, Christian J. Jacques, MD, Meletios A. Dimopoulos

Blood (2010) 116 (21): 622.

https://doi.org/10.1182/blood.V116.21.622.622

Published: 2010

Journal Articles

A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma

Philippe Moreau, Halyna V Pylypenko, Sebastian Grosicki, Evgeniy E Karamanesht, Xavier Leleu, Maria E Grishunina, Grigoriy B Rekhtman, Zvenyslava Masliak, Tadeusz Robak, Anna V Shubina, Jean-Paul Fermand, Martin Kropff, James Cavet, Sudha Parasuraman, Huaibao Feng, Donna M Skee, Helgi van de Velde, William M Deraedt, Jean-Luc Harousseau

Blood (2010) 116 (21): 312.

https://doi.org/10.1182/blood.V116.21.312.312

Published: 2010

Journal Articles

Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach

Bart Heeg, Michel van Agthoven, Johan Liwing, Ulf-Henrik Mellqvist, Torben Plesner, Floris Logman, Verena Donatz, Johan Aschan, Hermann Einsele, Martin Kropff, Maarten Treur, Mirjam Barendse, Jean-Luc Harousseau, Antonio Palumbo, Pieter Sonneveld

Blood (2010) 116 (21): 3046.

https://doi.org/10.1182/blood.V116.21.3046.3046

Published: 2010

Journal Articles

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

Jean-Luc Harousseau, Antonio Palumbo, Paul G. Richardson, Rudolf Schlag, Meletios A. Dimopoulos, Ofer Shpilberg, Martin Kropff, Alain Kentos, Michele Cavo, Anatoly Golenkov, Mieczyslaw Komarnicki, Maria-Victoria Mateos, Dixie-Lee Esseltine, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesús F. San Miguel

Blood (2010) 116 (19): 3743–3750.

https://doi.org/10.1182/blood-2010-03-275800

Published: 2010

Includes: Supplemental data

Journal Articles

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.

Blood (2009) 114 (22): 3859.

https://doi.org/10.1182/blood.V114.22.3859.3859

Published: 2009

Journal Articles

A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.

Antonio Palumbo, Meletios A. Dimopoulos, Michel Delforge, Martin Kropff, Robin Foa, Zhinuan Yu, Lindsay Herbein, Jay Mei, Christian Jacques, John Catalano

Blood (2009) 114 (22): 613.

https://doi.org/10.1182/blood.V114.22.613.613

Published: 2009

Journal Articles

Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).

Blood (2009) 114 (22): 131.

https://doi.org/10.1182/blood.V114.22.131.131

Published: 2009

Journal Articles

Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial

Blood (2008) 112 (11): 2776.

https://doi.org/10.1182/blood.V112.11.2776.2776

Published: 2008

NARROW

Bortezomib Consolidation Following Autologous Transplant Equalizes the Outcome for Older Patients with Less Intensive Pretreatment Compared to Younger Patients with Newly Diagnosed Multiple Myeloma

Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma: Final Results of a National Multicenter Randomized Controlled Phase III Study

Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Multiple Myeloma

PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

Analysis of Second-Line Lenalidomide Following Initial Relapse in the MM-015 Trial

Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years,

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression

Lenalidomide Maintenance Therapy After Toxicity-Reduced Myeloablative Allograft As Salvage Therapy for Efractory/Relapsed Myeloma Patients

A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients ≥ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens

A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma

Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.

OPTIMUM Dose of Thalidomide for Relapsed Multiple Myeloma.

A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.

Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial).

Bortezomib, Intravenous Cyclophosphamide and Dexamethasone (VelCD) for Previously Untreated Multiple Myeloma: An Interim Analysis of the German DSMM XIa Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only